🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Malignant Tumors

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors NCT07408258Phase 13 sites📍 New York📍 Philadelphia📍 Houston OncoC4, Inc. · Tests: ONC-783 A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation NCT06908434Phase 11 site📍 Shanghai Changchun GeneScience Pharmaceutical Co., Ltd. · Tests: GenSci128 tablets A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors NCT05866692Phase 12 sites📍 Beijing📍 Jinan TYK Medicines, Inc · Tests: TY-2699a VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors NCT06821048Phase 11 site📍 Hangzhou Weijia Fang, MD · Tests: Intraperitoneal infusion of FAST CEA-targeted CAR-T An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma NCT06008106Phase 31 site📍 Beijing Shanghai Kechow Pharma, Inc. · Tests: tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Naltrexone and Propranolol Combined With Immunotherapy NCT05968690Phase 11 site📍 New Brunswick Sarah Weiss · Tests: Propranolol, Naltrexone A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916Phase 122 sites📍 Duarte📍 La Jolla📍 Ann Arbor Incyte Corporation · Tests: INCA036873 A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors NCT05366478Phase 11 site📍 Tianjin Suzhou BlueHorse Therapeutics Co., Ltd. · Tests: Autologous tumor infiltrating lymphocytes (TILs) Study of GS-2426 in Participants With Advanced Solid Tumors NCT07601243Phase 16 sites📍 Boston📍 Grand Rapids📍 East Brunswick Gilead Sciences · Tests: GS-2426 A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors NCT06311578Phase 110 sites📍 New York📍 Philadelphia📍 Pittsburgh Johnson & Johnson Enterprise Innovation Inc. · Tests: JNJ-87704916, Cetrelimab, Standard of Care PD(L)-1 NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors NCT05881525Phase 11 site📍 Chongqing TCRCure Biopharma Ltd. · Tests: TC-N201 cells, IL-2, Fludarabine, Cyclophosphamide, Nab-paclitaxel A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors NCT04686682Phase 1, Phase 21 site📍 Tianjin Jacobio Pharmaceuticals Co., Ltd. · Tests: JAB-8263, JAB-8263 A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors NCT05142423Phase 1, Phase 21 site📍 Hangzhou Akeso · Tests: AK109+AK104 A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement NCT07359820Phase 219 sites📍 Phoenix📍 Jacksonville📍 Tampa Elevar Therapeutics · Tests: Lirafugratinib Plasmodium Immunotherapy for Advanced Malignant Solid Tumors NCT04165590Phase 1, Phase 21 site📍 Kunming CAS Lamvac Biotech Co., Ltd. · Tests: Plasmodium immunotherapy DXP-106 in Solid Tumor Patients. NCT07532018Phase 14 sites📍 Harbin📍 Shanghai📍 Taiyuan Singlomics Biopharmaceuticals Zhuhai Co., Ltd. · Tests: DXP-106 Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors NCT05584670Phase 1, Phase 222 sites📍 Newark📍 Iowa City📍 Westwood Sanofi · Tests: SAR445877, Cetuximab, ADG126, Bevacizumab, Nivolumab Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology NCT05756569Phase 24 sites📍 Atlanta📍 Atlanta📍 Atlanta Emory University · Tests: Biospecimen Collection, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours NCT06682780Phase 1, Phase 21 site📍 Shanghai LaNova Medicines Limited · Tests: LM-2417, Docetaxel, Toripalimab/Tirelizumab, Carboplatin, Niraparib A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors NCT07250386Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: CEA-targeted CAR-T (Intravenous), CEA-targeted CAR-T (Intrapleural) A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. NCT04116541Phase 213 sites📍 Angers📍 Bordeaux📍 Caen Centre Leon Berard · Tests: HDM201, Ribociclib, Cabozantinib, Alectinib, Regorafenib Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors NCT00870129NA1 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: MRI and advanced MRI sequences A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors NCT05932862Phase 116 sites📍 Fountain Valley📍 Jacksonville📍 Orlando Exelixis · Tests: XL309, Olaparib AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors NCT07174661NA1 site📍 Scottsdale Mayo Clinic · Tests: Advance Care Planning, Educational Intervention, Electronic Health Record Review, Survey Administration I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379Phase 242 sites📍 Birmingham📍 Scottsdale📍 Tucson QuantumLeap Healthcare Collaborative · Tests: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Tras…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy